Nurse Practitioners of New York

Doctors for America - prescriptions drugs

Posted over 1 year ago by Yonit Lipkind

As physicians and health providers, we know all too well that the price of prescription drugs affects the health of our patients. High prices for prescription drugs prevent many of our patients from accessing the treatments that they need, forcing many to choose between medications and rent as out of pocket costs grow.

Now Bristol-Myers Squibb is spending $74 billion to buy out a rival, Celgene. It would be the largest pharmaceutical merger ever. We've already seen the result of mergers in the pharma industry -- drug prices soar. It happened to the Epi-Pen. It happened with arthritis drugs. It even happened with insulin.

Tell the FTC: Oppose the latest Pharma Merger

The FTC must investigate and block the attempt by Bristol-Myers Squibb to buy out Celgene. This would be the largest pharmaceutical merger ever, and as with past mergers, the result will be less innovation and much higher prescription drug costs for the public. This mega-merger will block the development and sale of affordable drugs and reduce competition precisely at a moment when we need more of it.

We can't sit by and let Big Pharma get bigger. Take action and tell the FTC to stop this potential merger now.

Thanks for taking action,
Reshma Ramachandran, MD, MPP
Family Medicine resident at Kaiser Permanente Los Angeles Medical Center
Co-Chair of DFA - Prescription Drug Affordability Working Group

Doctors for America

Doctors for America